Pfizer has reported a marginal rise in net sales (excluding excise) for 1HFY03 ahead of its merger with Parke Davis. This seems mainly on the back of discontinuance of certain non-profitable brands ahead of the merger. The merger ratio has been finalised at 4:9 (i.e. 4 shares of Pfizer for every 9 shares of Parke Davis). Post the merger, Pfizer is expected to be the fifth largest player in the domestic pharma market.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share
P/E (at current price)
*- 1HFY03- is for the half year ending May'02.
The company reported a strong 210 basis points rise in operating margins. However, operating margins of the company are still lagging behind its peers. A closer look at the break-up of operating expenses suggest that there could be further improvement in operating margins going forward. While most of the cost heads have reported an improvement, staff costs recorded a rise on the back of integration of the field force of Parke Davis. The integration of the marketing staff of Parke Davis with Pfizer has already taken place.
Sales (Rs m)
Animal Healthcare Business
Services- Clinical Development
*- Profit before interest and tax
% of sales
Purchase of finished goods
Administrative and other costs
The boost in sales and operating margins seem to be on the back two main reasons. One, the company's 'Corex' range of cough preparations which contribute around 30% to Pfizer's sales are logging 8%-9% growth rates. Further, inspite of strong competition, new products like Magnex and Hepashield are selling at a premium.The merger with Parke Davis is expected to bring down the DPCO coverage of the company to around 19% of turnover against 24% at present. The government is yet to announce the final list of drugs under the new DPCO policy formulated early this year. Becousules (vitamin brand), which would contribute around 12% of the merged entity, is expected to come out of DPCO coverage. Becousules, a Rs 700 m product of Pfizer, is a very strong brand in the vitamin segment. Therefore, the company might be able to implement some price increase on the product.
At the current market price of Rs 454, the stock is trading at 16x our FY03 expected earnings on a consolidated basis. The company has set a target of logging double digit growth in topline and 20-25% growth in bottomline. This is on the back of greater focus on profitable brands and integration benefits. The final DPCO list may also act as a trigger for the company's stock price.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407